6 Gastroenterology Headlines You Missed in August 2026

Gastroenterology news this month spanned oncology, inflammatory bowel disease (IBD), and screening research.

On August 26, 2026, the US Food and Drug Administration (FDA) approved daraxonrasib (Rasonque), a first-in-class oral RAS inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. The approval was based on phase 3 RASolute 302 data showing a median overall survival of 13.2 months versus 6.7 months with chemotherapy.

In ulcerative colitis (UC), Remo Panaccione, MD, of the University of Calgary discussed phase 3 ABTECT maintenance data showing obefazimod sustained clinical remission through week 44, including in patients who had not initially responded to induction therapy. Abivax is planning an NDA submission in the fourth quarter of 2026.

A reanalysis of Sweden's Stockholm-Gotland screening program, discussed by Johannes Blom, MD, PhD, of the Karolinska Institute, found that correcting for contamination bias and nonadherence raised the estimated mortality reduction from actual participation in colorectal cancer screening to 43%, well above the original 14% estimate.

Elsewhere, Andrew Chan, MD, MPH, of Massachusetts General Hospital discussed a 2-decade cohort study linking sugar-sweetened beverage intake to higher gastric cancer incidence, with no similar association for artificially sweetened beverages. And Elizabeth Spencer, MD, of the Icahn School of Medicine at Mount Sinai discussed new findings tying prenatal exposure to PFAS, or "forever chemicals," to elevated markers of intestinal inflammation in children as old as age 6, a signal relevant to future IBD risk.

Regulatory Updates

FDA Approves First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer

The FDA approved daraxonrasib (Rasonque), a first-in-class RAS(ON) multi-selective inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.

In the phase 3 RASolute 302 trial, daraxonrasib produced a median overall survival of 13.2 months compared with 6.7 months with chemotherapy.

That's a roughly 60% reduction in the risk of death. Common side effects included rash, diarrhea, and fatigue.

Trial Data

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD

Related: ABTECT Part 2 Data: Obefazimod Sustains Remission in UC

Remo Panaccione, MD, of the University of Calgary discussed phase 3 ABTECT maintenance data for obefazimod in moderate-to-severe ulcerative colitis.

At week 44, both the 25 mg and 50 mg doses achieved clinical remission in about 51% of patients, compared with 10% on placebo. That included patients who had not initially responded to induction.

Endoscopic remission reached 41.5% and 47.7% with the two doses, respectively. Panaccione said no new safety signals emerged across more than 1,700 patient-years of exposure.

Abivax plans to submit an NDA in the fourth quarter of 2026.

43% Lower Mortality Seen in Colorectal Screening Participants

Johannes Blom, MD, PhD, of the Karolinska Institute discussed a reanalysis of Sweden's Stockholm-Gotland fecal occult blood test screening program that corrected for contamination bias and nonadherence.

Invitation to screening was associated with a 26% reduction in colorectal cancer mortality, up from an original 14% estimate.

Actual participation in screening was associated with a 43% reduction.

Expert Perspective

Sugar-Sweetened Beverages Associated With Increased Gastric Cancer Risk, With Andrew Chan, MD, MPH

Andrew Chan, MD, MPH, of Massachusetts General Hospital discussed a 2-decade cohort study of 112,284 participants published in Gastro Hep Advances.

Daily intake of more than one sugar-sweetened beverage was associated with substantially higher gastric cancer incidence compared with never consuming them. Artificially sweetened beverages showed no similar link.

Chan said the finding points to a possible connection between metabolic dysfunction and gastric cancer risk that hasn't been well characterized before.

"Forever Chemicals" Are in Cord Blood And Tied to Gut Inflammation in Kids

Elizabeth Spencer, MD, of the Icahn School of Medicine at Mount Sinai discussed a new analysis linking early-life exposure to PFAS, or "forever chemicals," to elevated fecal calprotectin, a marker of intestinal inflammation, in children up to age 6 across three birth cohorts.

Mothers with IBD had higher levels of the same PFAS metabolites most linked to their children's elevated calprotectin.

Spencer noted that none of the children studied have been diagnosed with IBD, and cautioned the findings represent an association rather than a proven causal pathway.